Biogen's Alzheimer's drug blocked in Japan

The Japanese health authorities won't approve Biogen's Aduhelm, a treatment for Alzheimer's disease, without first receiving additional data.

Photo: POOL New/VIA REUTERS / X80003

Alzheimer's drug Aduhelm, which is marketed in a collaboration between Biogen and Eisai, is facing many problems -- the latest of which is found in Japan.

Friday's rejection of Aduhelm in the EU has been followed by a similar decision in Japan, where the national health authority is requiring more data pertaining to the drug's efficacy, the companies report in a shared statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs